News Image

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -

Read more at globenewswire.com

SOLID BIOSCIENCES INC

NASDAQ:SLDB (2/11/2025, 12:08:00 PM)

3.16

-0.28 (-8.14%)

SLDB Latest News and Analysis

Follow ChartMill for more